David J Irwin1,2, Johannes Brettschneider3, Corey T McMillan1, Felicia Cooper1,2, Christopher Olm1, Steven E Arnold4, Vivianna M Van Deerlin2, William W Seeley5, Bruce L Miller5, Edward B Lee2,6, Virginia M-Y Lee2, Murray Grossman1, John Q Trojanowski2. 1. University of Pennsylvania Frontotemporal Degeneration Center, Department of Neurology, University of Pennsylvania, Philadelphia, PA. 2. Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA. 3. Department of Neurology, Herford Hospital, Herford, Germany. 4. Brain-Behavior Laboratory, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 5. Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA. 6. Translational Neuropathology Research Laboratory, University of Pennsylvania, Philadelphia, PA.
Abstract
OBJECTIVE: To characterize sequential patterns of regional neuropathology and clinical symptoms in a well-characterized cohort of 21 patients with autopsy-confirmed Pick disease. METHODS: Detailed neuropathological examination using 70μm and traditional 6μm sections was performed using thioflavin-S staining and immunohistochemistry for phosphorylated tau, 3R and 4R tau isoforms, ubiquitin, and C-terminally truncated tau. Patterns of regional tau deposition were correlated with clinical data. In a subset of cases (n = 5), converging evidence was obtained using antemortem neuroimaging measures of gray and white matter integrity. RESULTS: Four sequential patterns of pathological tau deposition were identified starting in frontotemporal limbic/paralimbic and neocortical regions (phase I). Sequential involvement was seen in subcortical structures, including basal ganglia, locus coeruleus, and raphe nuclei (phase II), followed by primary motor cortex and precerebellar nuclei (phase III) and finally visual cortex in the most severe (phase IV) cases. Behavioral variant frontotemporal dementia was the predominant clinical phenotype (18 of 21), but all patients eventually developed a social comportment disorder. Pathological tau phases reflected the evolution of clinical symptoms and degeneration on serial antemortem neuroimaging, directly correlated with disease duration and inversely correlated with brain weight at autopsy. The majority of neuronal and glial tau inclusions were 3R tau-positive and 4R tau-negative in sporadic cases. There was a relative abundance of mature tau pathology markers in frontotemporal limbic/paralimbic regions compared to neocortical regions. INTERPRETATION: Pick disease tau neuropathology may originate in limbic/paralimbic cortices. The patterns of tau pathology observed here provide novel insights into the natural history and biology of tau-mediated neurodegeneration.
OBJECTIVE: To characterize sequential patterns of regional neuropathology and clinical symptoms in a well-characterized cohort of 21 patients with autopsy-confirmed Pick disease. METHODS: Detailed neuropathological examination using 70μm and traditional 6μm sections was performed using thioflavin-S staining and immunohistochemistry for phosphorylated tau, 3R and 4R tau isoforms, ubiquitin, and C-terminally truncated tau. Patterns of regional tau deposition were correlated with clinical data. In a subset of cases (n = 5), converging evidence was obtained using antemortem neuroimaging measures of gray and white matter integrity. RESULTS: Four sequential patterns of pathological tau deposition were identified starting in frontotemporal limbic/paralimbic and neocortical regions (phase I). Sequential involvement was seen in subcortical structures, including basal ganglia, locus coeruleus, and raphe nuclei (phase II), followed by primary motor cortex and precerebellar nuclei (phase III) and finally visual cortex in the most severe (phase IV) cases. Behavioral variant frontotemporal dementia was the predominant clinical phenotype (18 of 21), but all patients eventually developed a social comportment disorder. Pathological tau phases reflected the evolution of clinical symptoms and degeneration on serial antemortem neuroimaging, directly correlated with disease duration and inversely correlated with brain weight at autopsy. The majority of neuronal and glial tau inclusions were 3R tau-positive and 4R tau-negative in sporadic cases. There was a relative abundance of mature tau pathology markers in frontotemporal limbic/paralimbic regions compared to neocortical regions. INTERPRETATION:Pick disease tau neuropathology may originate in limbic/paralimbic cortices. The patterns of tau pathology observed here provide novel insights into the natural history and biology of tau-mediated neurodegeneration.
Authors: Susumu Mori; Kenichi Oishi; Hangyi Jiang; Li Jiang; Xin Li; Kazi Akhter; Kegang Hua; Andreia V Faria; Asif Mahmood; Roger Woods; Arthur W Toga; G Bruce Pike; Pedro Rosa Neto; Alan Evans; Jiangyang Zhang; Hao Huang; Michael I Miller; Peter van Zijl; John Mazziotta Journal: Neuroimage Date: 2008-01-03 Impact factor: 6.556
Authors: William W Seeley; Danielle A Carlin; John M Allman; Marcelo N Macedo; Clarissa Bush; Bruce L Miller; Stephen J Dearmond Journal: Ann Neurol Date: 2006-12 Impact factor: 10.422
Authors: Angela L Guillozet-Bongaarts; Kelly E Glajch; Emilie G Libson; Michael E Cahill; Eileen Bigio; Robert W Berry; Lester I Binder Journal: Acta Neuropathol Date: 2007-03-15 Impact factor: 17.088
Authors: Vivianna M Van Deerlin; Mark S Forman; Jennifer M Farmer; Murray Grossman; Sonali Joyce; Alex Crowe; John Q Trojanowski; Virginia M-Y Lee; Anjan Chatterjee Journal: Acta Neuropathol Date: 2006-10-28 Impact factor: 17.088
Authors: William W Seeley; Richard Crawford; Katya Rascovsky; Joel H Kramer; Michael Weiner; Bruce L Miller; Maria Luisa Gorno-Tempini Journal: Arch Neurol Date: 2008-02
Authors: Jennifer L Whitwell; Keith A Josephs; Martin N Rossor; John M Stevens; Tamas Revesz; Janice L Holton; Safa Al-Sarraj; Alison K Godbolt; Nick C Fox; Jason D Warren Journal: Arch Neurol Date: 2005-09
Authors: Ian R A Mackenzie; Manuela Neumann; Eileen H Bigio; Nigel J Cairns; Irina Alafuzoff; Jillian Kril; Gabor G Kovacs; Bernardino Ghetti; Glenda Halliday; Ida E Holm; Paul G Ince; Wouter Kamphorst; Tamas Revesz; Annemieke J M Rozemuller; Samir Kumar-Singh; Haruhiko Akiyama; Atik Baborie; Salvatore Spina; Dennis W Dickson; John Q Trojanowski; David M A Mann Journal: Acta Neuropathol Date: 2009-11-19 Impact factor: 17.088
Authors: David J Irwin; Alberto Lleó; Sharon X Xie; Corey T McMillan; David A Wolk; Edward B Lee; Viviana M Van Deerlin; Leslie M Shaw; John Q Trojanowski; Murray Grossman Journal: Ann Neurol Date: 2017-08-19 Impact factor: 10.422
Authors: Gabor G Kovacs; Linda K Kwong; Murray Grossman; David J Irwin; Edward B Lee; John L Robinson; Eunran Suh; Vivianna M Van Deerlin; Virginia M Lee; John Q Trojanowski Journal: Brain Pathol Date: 2017-01-19 Impact factor: 6.508
Authors: Emilia M Gatto; Ricardo F Allegri; Gustavo Da Prat; Patricio Chrem Mendez; David S Hanna; Michael O Dorschner; Ezequiel I Surace; Cyrus P Zabetian; Ignacio F Mata Journal: Neurobiol Aging Date: 2017-02-10 Impact factor: 4.673
Authors: Gabor G Kovacs; John L Robinson; Sharon X Xie; Edward B Lee; Murray Grossman; David A Wolk; David J Irwin; Dan Weintraub; Christopher F Kim; Theresa Schuck; Ahmed Yousef; Stephanie T Wagner; Eunran Suh; Vivianna M Van Deerlin; Virginia M-Y Lee; John Q Trojanowski Journal: J Neuropathol Exp Neurol Date: 2017-04-01 Impact factor: 3.685
Authors: David J Irwin; Corey T McMillan; Sharon X Xie; Katya Rascovsky; Vivianna M Van Deerlin; H Branch Coslett; Roy Hamilton; Geoffrey K Aguirre; Edward B Lee; Virginia M Y Lee; John Q Trojanowski; Murray Grossman Journal: Brain Date: 2018-01-01 Impact factor: 13.501
Authors: Lucia A A Giannini; Sharon X Xie; Corey T McMillan; Mendy Liang; Andrew Williams; Charles Jester; Katya Rascovsky; David A Wolk; Sharon Ash; Edward B Lee; John Q Trojanowski; Murray Grossman; David J Irwin Journal: Ann Neurol Date: 2019-03-28 Impact factor: 10.422
Authors: Alberto Lleó; David J Irwin; Ignacio Illán-Gala; Corey T McMillan; David A Wolk; Edward B Lee; Vivianna M Van Deerlin; Leslie M Shaw; John Q Trojanowski; Murray Grossman Journal: JAMA Neurol Date: 2018-06-01 Impact factor: 18.302